What tesamorelin is
Tesamorelin is a stabilized analog of human GHRH(1-44). It does not add growth hormone to the body.
The GHRH analog with an FDA label, and what it is actually for
Tesamorelin is a stabilized analog of human GHRH(1-44). It does not add growth hormone to the body. It hands the pituitary the same start signal the hypothalamus uses, so the gland releases pulses of its own growth hormone.
This unit sets the honest picture first. It traces what tesamorelin is, why it is approved only for HIV-associated lipodystrophy, why the effect is visceral-fat reduction rather than weight loss, and where the evidence is strong and where it thins out.
What you'll learn
- What tesamorelin is and why the hexenoyl cap on GHRH(1-44) is the whole modification
- How amplifying growth hormone raises IGF-1, and why visceral fat falls while subcutaneous fat is spared
- How to read the Falutz phase 3 lipodystrophy trials and the NAFLD evidence tier by tier
- How the approved product is dosed and monitored, and its real safety signals
- Where tesamorelin sits among sermorelin, CJC-1295, ipamorelin, MK-677, and recombinant GH
- Its regulatory status: FDA approved for HIV lipodystrophy only, off-label elsewhere, and named on the WADA prohibited list
What this course covers
11 units take you from the essentials to an in-depth understanding.
- 01 What tesamorelin is The GHRH analog with an FDA label, and what it is actually for free
- 02 GHRH(1-44) biology and the receptor The full-length hormone, the class B receptor, and one GH pulse paid
- 03 Stabilization: the hexenoyl cap on the N-terminus One chemical change that turns minutes into a usable daily drug paid
- 04 Preserved pulsatility and the IGF-1 axis A pulse the axis still governs, and where the fat goes paid
- 05 HIV-associated lipodystrophy The one condition tesamorelin was built for, and why paid
- 06 The Falutz phase 3 trials The pivotal evidence: what the phase 3 program actually showed paid
- 07 Liver fat: the NAFLD evidence The promising second act: reducing liver fat, still off-label paid
- 08 Dosing, monitoring, and safety How the approved product is dosed and watched, and what can go wrong paid
- 09 The GH-axis landscape Tesamorelin among the secretagogues, analogs, and recombinant GH paid
- 10 Regulatory status and access Approved, narrow, and prohibited in sport paid
- 11 Final exam and certification Pass the final exam to earn your certificate of completion. Exam
Key terms
The one-line mechanism
Before any detail, hold the whole idea in one sentence. Tesamorelin does not pour growth hormone into the body. It gives the pituitary the same signal the hypothalamus uses, the gland releases a pulse of its own GH, and that raises IGF-1. What the trials then observed is a fall in the visceral fat depot.
Because the pituitary and its feedback loops stay in charge, the drug works inside the axis: multiple negative feedback mechanisms detect changes in circulating GH or IGF-1 at both the pituitary and the hypothalamus. Working with the axis rather than overriding it is the thread of the whole course, and unit 4 shows what that feedback does and does not limit.
AdvancedWhy "your own GH" is the honest framing
Recombinant growth hormone adds the hormone from outside; tesamorelin asks the pituitary for it instead. The general physiology is well described: growth hormone circulates in a pulsatile pattern, GHRH is the primary regulator of that pattern, somatostatin counteracts it, other data implicate somatostatin as the key regulator of secretory timing and amplitude, and multiple negative feedback mechanisms detect changes in circulating GH or IGF-1 at both the pituitary and the hypothalamus. On tesamorelin itself, the sources behind this course offer statements and levels rather than a pulse analysis: a review and a trial introduction state that it restores pulsatile GH secretion, the 2014 liver trial found mean overnight GH higher on drug than on placebo, and IGF-1 rose 81.0 percent in the first phase 3 trial. The pharmacologic case for working with the axis is a well-argued inference from where the drug acts, not a published analysis of its pulses.
Discovery and approval
Tesamorelin, developed as TH9507, answered a specific problem: sermorelin, the bare GHRH fragment, is cleared within about 10 to 20 minutes in humans, largely by renal filtration and enzymatic degradation at its N terminus. A stabilizing cap on the N-terminal tyrosine of GHRH(1-44) was the answer tesamorelin took, a hexenoyl moiety in the label’s own words, and the phase 3 program earned it FDA approval in November 2010.
The framing that matters is scope. Tesamorelin is approved for one narrow indication, the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, not for general body recomposition. Its Drugs@FDA record lists the approved product, Egrifta, as a prescription drug.
AdvancedWhy the unmet need was so specific
Older antiretroviral regimens came with a disfiguring central-fat accumulation, reported as common in patients taking NRTIs and protease inhibitors, and the closest pharmacologic answer did not win an indication for it: growth hormone did not receive FDA approval for reducing abdominal fat in HIV despite efficacy in trials. Recombinant GH reduced visceral fat but worsened insulin sensitivity. Tesamorelin took the other route, raising the body’s own growth hormone, and it is the one that won the indication.
Visceral fat, not weight loss
The most common misconception is that tesamorelin is a weight-loss drug. It is not. It preferentially reduces visceral fat around the organs while largely sparing the fat under the skin, so total body weight changes little. The indication the label writes is abdominal fat; what the trials measured was the deep visceral depot, on a CT scan.
This distinction is clinically the point. In HIV lipodystrophy, peripheral fat is often already lost, so a drug that targets the visceral depot and spares the rest is precisely what the population needs.
AdvancedWhy visceral fat is the depot worth targeting
The usual account is that visceral fat feeds free fatty acids to the liver through the portal vein. A body-fat-distribution review supports part of that: in upper body obesity, portal free fatty acid concentrations may be significantly greater than arterial ones, exposing the liver to more of them. The same abstract also notes that upper body subcutaneous fat delivers the majority of free fatty acids to the general circulation, so the portal route is a visceral-specific addition rather than the whole story, and no source here measures it in a treated patient. What the link does not establish is a clinical outcome, and the label says as much in its limitations of use: long-term cardiovascular safety of Egrifta SV has not been established. Visceral fat is a well-argued target on mechanism and on surrogate endpoints, not a proven route to fewer cardiovascular events.
The honest evidence ceiling
Tesamorelin invites hype, so set the ceiling before the science. Unlike most peptides in this space, its approved use rests on phase 3 trials, but that strength does not transfer to the off-label promises made around it.
Keeping these tiers apart is the discipline of the course. The lipodystrophy data are genuinely strong, the liver-fat data are promising, and the sweeping non-HIV promises rest on extrapolation. Confusing one tier for another is how honest education slides into marketing.
This course is education, not medical advice. Nothing here is a recommendation to use tesamorelin. It is FDA-approved only for HIV-associated lipodystrophy; all other use is off-label and not supported by large trials.
Popular claims, checked
A few claims you will meet online, held against the tiers above. Most are not simply false. They are real but narrow findings that get rounded up into transformations as they travel from journals to sales pages.
The skill this course builds is reading each claim against its tier. When a source states an exact off-label benefit with confidence, that confidence itself is usually the red flag.